Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | BEGONIA: durvalumab combinations in advanced TNBC

Peter Schmid, MD, PhD, FRCP, Barts Cancer Institute, London, UK, discusses the BEGONIA study (NCT03742102), a Phsae Ib/II study of durvalumab combinations in locally advanced/metastatic triple-negative breast cancer (TNBC). This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.